Your direct line with Barcelona

The World Congress on Gastrointestinal Cancer 2023 brings together leading experts in the field of gastroinestinal cancer from around the world. And, as usual, they gather together in Barelona, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.

Stay tuned, and get ready for an exciting and informative journey!

With the educational support of

Daily highlights

Highlight 5: colorectal cancer

In this highlight video, we are fortunate to have Dr Francesco Sclafani sharing the highlights. Dr Sclafani will delve into a range of compelling topics surrounding colorectal cancer, which were thoughtfully presented during the session held on Saturday.

Dr. Sclafani initiates

See video »

Highlight 4: hepatocellular cancer

Dr Jochen Decaestecker focuses in this highlight video on key advancements and noteworthy developments in the field of hepatocellular cancer.

Dr Decaestecker initially discusses the presentation delivered by Prof. Jessica Zucman-Rossi from Université Paris Cité. She provided valuable insights into the

See video »

Highlight 3: colorectal cancer

Dr Vandamme’s discussion revolves around two important topics. Firstly, he highlights the use of ctDNA (circulating tumour DNA) as a tool for guiding treatment decisions in colorectal cancer. Secondly, Dr Vandamme focuses on mutational signatures and the role of Homologous

See video »

Highlight 2: esophageal and gastric cancer

Dr Eduard Callebout, working at UZ Gent, highlights key presentations from the session on oesophageal and stomach cancers at the 25th World Congress on Gastrointestinal Cancer in Barcelona. His video provides valuable insights into the latest developments in the field.


See video »

Highlight 1: pancreatic and biliary cancer

Dr Willem Lybaert brings us the daily highlights on pancreatic and biliary cancer. He delves into four notable studies, two of which focus on pancreatic cancer.

The first study, known as the NAPOLI 3 STUDY, compares the efficacy of NALIRIFOX

See video »

In-depth stories

The SUNLIGHT study

The SUNLIGHT study holds significant importance in the field of colorectal cancer, specifically in the third-line treatment setting. It is the first study to compare two active regimens in this particular context. The study investigated the addition of bevacizumab to

See video »


Prof Dr Bruno Sangro presents the updated Phase III HIMALAYA study analysis. The study evaluated the efficacy and safety of the STRIDE regimen, consisting of a single priming dose of tremelimumab plus durvalumab, compared to sorafenib in patients with unresectable

See video »

FIGHT Study in Gastric/Gastroesophageal Junction Cancer

Prof Dr Zev Wainberg presents the final analysis of the FIGHT Trial. This significant study investigated the efficacy of bemarituzumab, a monoclonal antibody that selectively inhibits FGFR2b signalling and enhances antibody-dependent cellular toxicity against tumour cells expressing FGFR2b. The trial

See video »

Poster selection

Induction chemotherapy

Charlène van der Zijden from the Erasmus MC Cancer Institute in Rotterdam on induction chemotherapy followed by restaging after surgery for advanced esophageal cancer.

See video »

The PD-8 HERIZON study

Joshua Tobias, affiliated with the Medical University of Vienna, on the PD-8 HERIZON. A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine plus SOC chemotherapy in patients with HER2+ advanced stomach cancer.

See video »

Z1. Researchpark 30, 1731 Zellik, Belgium
Website created by MediMix © 2023 - Privacy Policy